Non-tuberculous mycobacterial pulmonary infections

Non-tuberculous mycobacterial (NTM) infections are increasingly rapidly worldwide. The reason for this phenomenon is unclear, but may include the ageing population, the increasing use of immunosuppressive drugs, the increasing prevalence of diseases that confer susceptibility to NTM, such as COPD an...

Full description

Bibliographic Details
Main Authors: J.D. Chalmers, T. Aksamit, A.C.C. Carvalho, A. Rendon, I. Franco
Format: Article
Language:English
Published: Elsevier España 2018-03-01
Series:Pulmonology
Online Access:http://www.sciencedirect.com/science/article/pii/S2531043718300199
id doaj-f66f6bfeea3b42f49fd1afe5bd82be25
record_format Article
spelling doaj-f66f6bfeea3b42f49fd1afe5bd82be252020-11-25T03:27:01ZengElsevier EspañaPulmonology2531-04372018-03-01242120131Non-tuberculous mycobacterial pulmonary infectionsJ.D. Chalmers0T. Aksamit1A.C.C. Carvalho2A. Rendon3I. Franco4Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom; Corresponding author.Mayo Clinic College of Medicine, Rochester, MN, USALaboratory of Innovation in Therapies, Education and Bioproducts (LITEB), Oswaldo Cruz Institute IOC, Fiocruz, Rio de Janeiro, BrazilHospital Universitario de Monterrey, Centro de Investigación, Prevención y Tratamiento de Infecciones Respiratorias, Monterrey, Nuevo León UANL, MexicoRespiratory Department, Centro Hospitalar Vila Nova de Gaia/Espinho, PortugalNon-tuberculous mycobacterial (NTM) infections are increasingly rapidly worldwide. The reason for this phenomenon is unclear, but may include the ageing population, the increasing use of immunosuppressive drugs, the increasing prevalence of diseases that confer susceptibility to NTM, such as COPD and bronchiectasis, and growing testing for NTM. Awareness of the NTM related diseases is rising but is still suboptimal. Guidelines from the American Thoracic Society and Infectious Diseases Society of America have provided a framework for evaluating disease and evaluating care. Compliance with these guidelines is, however, very poor globally.NTM infections are amongst the most challenging cases that respiratory and infectious diseases physicians face. The challenges include intrinsic antibiotic resistance, complex drug regimens, poor tolerability and significant side effects associated with therapy and poor response rates. The decision to initiate treatment is therefore often difficult and requires careful evaluation of benefits and risks. Optimal management of NTM infections requires multidisciplinary care with close collaboration between physicians, microbiologists, physiotherapist/allied health professionals, primary care physicians and the patient.There remains a need for greater research into the epidemiology, clinical evaluation and treatment of NTM pulmonary disease. Randomised clinical trials are now being conducted which may provide useful data on the effectiveness of some new and existing therapies.In this review, we discuss the growing importance of NTM pulmonary disease and the opportunities for progress in clinical research for these conditions. Keywords: NTM guidelines, Bronchiectasis, COPD research, Antibioticshttp://www.sciencedirect.com/science/article/pii/S2531043718300199
collection DOAJ
language English
format Article
sources DOAJ
author J.D. Chalmers
T. Aksamit
A.C.C. Carvalho
A. Rendon
I. Franco
spellingShingle J.D. Chalmers
T. Aksamit
A.C.C. Carvalho
A. Rendon
I. Franco
Non-tuberculous mycobacterial pulmonary infections
Pulmonology
author_facet J.D. Chalmers
T. Aksamit
A.C.C. Carvalho
A. Rendon
I. Franco
author_sort J.D. Chalmers
title Non-tuberculous mycobacterial pulmonary infections
title_short Non-tuberculous mycobacterial pulmonary infections
title_full Non-tuberculous mycobacterial pulmonary infections
title_fullStr Non-tuberculous mycobacterial pulmonary infections
title_full_unstemmed Non-tuberculous mycobacterial pulmonary infections
title_sort non-tuberculous mycobacterial pulmonary infections
publisher Elsevier España
series Pulmonology
issn 2531-0437
publishDate 2018-03-01
description Non-tuberculous mycobacterial (NTM) infections are increasingly rapidly worldwide. The reason for this phenomenon is unclear, but may include the ageing population, the increasing use of immunosuppressive drugs, the increasing prevalence of diseases that confer susceptibility to NTM, such as COPD and bronchiectasis, and growing testing for NTM. Awareness of the NTM related diseases is rising but is still suboptimal. Guidelines from the American Thoracic Society and Infectious Diseases Society of America have provided a framework for evaluating disease and evaluating care. Compliance with these guidelines is, however, very poor globally.NTM infections are amongst the most challenging cases that respiratory and infectious diseases physicians face. The challenges include intrinsic antibiotic resistance, complex drug regimens, poor tolerability and significant side effects associated with therapy and poor response rates. The decision to initiate treatment is therefore often difficult and requires careful evaluation of benefits and risks. Optimal management of NTM infections requires multidisciplinary care with close collaboration between physicians, microbiologists, physiotherapist/allied health professionals, primary care physicians and the patient.There remains a need for greater research into the epidemiology, clinical evaluation and treatment of NTM pulmonary disease. Randomised clinical trials are now being conducted which may provide useful data on the effectiveness of some new and existing therapies.In this review, we discuss the growing importance of NTM pulmonary disease and the opportunities for progress in clinical research for these conditions. Keywords: NTM guidelines, Bronchiectasis, COPD research, Antibiotics
url http://www.sciencedirect.com/science/article/pii/S2531043718300199
work_keys_str_mv AT jdchalmers nontuberculousmycobacterialpulmonaryinfections
AT taksamit nontuberculousmycobacterialpulmonaryinfections
AT acccarvalho nontuberculousmycobacterialpulmonaryinfections
AT arendon nontuberculousmycobacterialpulmonaryinfections
AT ifranco nontuberculousmycobacterialpulmonaryinfections
_version_ 1724589921582186496